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Total vitamin D levels had been commonly reported to be lowered in patients with chronic psychotic ill-
nesses in countries from the higher latitudes. However, studies on patients with ﬁrst episode psychosis
(FEP) are limited. In this study we investigated serum concentrations of total and bioavailable vitamin D
levels in FEP patients compared to healthy controls and the association between symptom severity and
vitamin D components. A total of 31 FEP patients and 31 healthy controls were recruited from Institute of
Mental Health, Singapore. FEP patients were identiﬁed using Structured Clinical Interview for DSM-IV Axis I
disorders (SCID-1) and severity symptoms were assessed using the positive and negative syndrome scale
(PANSS). Sera from participants were analyzed for total vitamin D, vitamin D-binding protein (DBP) and
bioavailable vitamin D. Linear regressions were performed to examine the associations between serum total
and bioavailable vitamin D and the PANSS subscales. Current study noted a signiﬁcantly lower bioavailable
vitamin D was in the FEP group and an association between bioavailable vitamin D and negative symptoms
in FEP patients in a population with a consistent supply of sun exposure throughout the year.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is an increasing focus on the importance of vitamin D
levels in mental health (Graham et al., 2015). A growing body of
evidence suggests that vitamin D plays neuroprotective roles in a
number of brain processes including neurodevelopment, neuro-
transmitter expression, neurotropic and growth factor regulation
(Eyles et al., 2013). Its receptor and enzyme are required for hy-
droxylation to active form and 1-α-hydroxylase is reportedly
expressed in many brain regions (hippocampus, thalamus, hy-
pothalamus, amygdala, prefrontal cortex, cingulate gyrus and
temporal lobe) which are associated to psychosis (Eyles et al., 2005).
Total vitamin D is hydroxylated in the liver and kidneys to
produce 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin (Johnsen
et al., 2014). 85–90% of these metabolites are then circulated via
binding to DBP and approximately 1% of the metabolites bind
weakly to albumin to circulate in the bloodstream (Johnsen et al.,
2014). Based on the free-hormone hypothesis, the free fraction of a
hormone is the biologically active component (Johnsen et al., 2014).
Therefore, bioavailable vitamin D is believed to correlate more
strongly with biological actions of vitamin D (Johnsen et al., 2014).Ireland Ltd. This is an open acces
.Recent meta-analyses reported signiﬁcantly lower serum total
vitamin D levels in patients with psychiatric disorders, especially
in schizophrenia when compared to healthy controls (Belvederi
Murri et al., 2013; Valipour et al., 2014). These studies focused on
both chronic patients in European and non-European populations
(Abdullah et al., 2012; Graham et al., 2015; Higuchi et al., 1987;
Itzhaky et al., 2012; Jamilian et al., 2013; Menkes et al., 2012;
Norelli et al., 2010; Yüksel et al., 2014). Thus far, only three studies
have been conducted in patients with ﬁrst episode psychosis (FEP)
and their ﬁndings are equivocal. Crews et al. found signiﬁcantly
lower total vitamin D level in both white and black patients but
not in Asian patients, compared to healthy controls (Crews et al.,
2013). Graham et al., on the other hand did not ﬁnd any patient/
control differences (Graham et al., 2015). The latest study in 2015
by Nerhus et al. found no difference between ﬁrst and multiple
episode patients with psychosis and healthy controls (Nerhus
et al., 2015).
Several observational studies suggested vitamin D levels to be
related to the development of psychosis. Many studies had also
reported on the correlation between early life vitamin D statuses
and the development of schizophrenia from as early as 1977. One
related observation was an increase in schizophrenia births during
winter when vitamin D deﬁciency was expected be to more pre-
valent (Torrey et al., 1977). Another study reported on thes article under the CC BY-NC-ND license
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risk after relocation to higher latitudes with reduced sun exposure
(Dealberto, 2007). A Swedish cohort study reported a lowered risk
of psychotic symptoms in woman with high intake of ﬁsh, omega-
3 or omega-6 PUFA and vitamin D intake (Hedelin et al., 2010).
Similarly, the risk of developing schizophrenia was reduced in
Finnish male infants who were given 2000 IU of daily vitamin D
supplement during their ﬁrst year of life (McGrath et al., 2004).
Several studies too reported a relationship between low vitamin D
levels during prenatal and early life and schizophrenia in United
States, Finland and Australia and suicide rates in active military
members (McGrath et al., 2004; McGrath et al., 2010; Torrey et al.,
1977; Umhau et al., 2013).
Much of the focus in vitamin D status had been on populations
living at higher latitudes with seasonal periods, with limited work
done in populations living closer to the equator as one may as-
sume variation in vitamin D between sub-populations is unlikely
in regions with regular sunlight. There are also numerous studies
reporting differential vitamin D levels among HIV patients
(Phabphal et al., 2009; Wiboonchutikul et al., 2012), epileptic pa-
tients (Phabphal et al., 2009), patients with hip fractures (Ramason
et al., 2014), obese children (Khor et al., 2011; Moy and Bulgiba,
2011) and healthy populations (Hawkins, 2013; Hawkins, 2009;
Nurbazlin et al., 2013; Wakayo et al., 2015) in countries with
regular sun exposure.
To the best of our knowledge, there is no published study ex-
amining total and bioavailable vitamin D levels in FEP patients
from a speciﬁc geographic location of tropical setting with regular
sun exposure. Thus, current study aims to evaluate and compare
serum levels of total and bioavailable vitamin D in patients with
FEP and healthy controls based in Singapore, as well as to compare
the relationships between serum levels of total and bioavailable
vitamin D with symptom severity (Jiang et al., 2013).2. Materials and methods
2.1. Study participants
The current study was conducted at the institute of Mental
Health, Singapore. Cases were individuals diagnosed with FEP and
have not exceeded 4 weeks of anti-psychotic treatment. Controls
were healthy individuals with no past history of mental illness.
Controls were matched for age, ethnicity and gender. Ethics ap-
proval for the study was provided by the Domain Speciﬁc Review
Board of the National Healthcare Group, Singapore.
2.2. Data collection
Socio-demographic data such as age, gender, ethnicity, current
smoking status, height, weight, and duration of untreated psy-
chosis (DUP) were obtained from all study participants.
2.3. Assessments
All FEP participants were assessed using the SCID-1. Clinical
symptoms were assessed on the PANSS by trained raters with
established inter-rater reliability at 40.8. Controls were assessed
on the SCID-I to determine history of mental illness at recruitment.
2.4. Measurement and calculation of serum DBP and vitamin D
components
Venous blood was collected from all study participants into
serum separating tubes. After blood collection, blood samples
were allowed to coagulate at room temperature for 30 min,centrifuged at 4 °C and serum collected. Serum total vitamin D,
albumin and calcium levels were determined by chemilumines-
cence immunoassay. DBP concentrations were measured by com-
mercial enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, USA).
Calculations for bioavailable vitamin D were done using a
general formula formulated by Vermeulen et al. (1999) and ad-
justed for vitamin D speciﬁcally by Powe et al. (2013) (see Sup-
plementary material).
2.5. Statistical analysis
Data was analyzed on SPSS Statistics version 23 (IBM Co., Ar-
monk, NY, USA). Descriptive statistics were tabulated for case and
control groups. Statistical signiﬁcance was set at po0.05 and was
examined using chi-squared test for categorical variables and ei-
ther independent Student's t-test or Mann-Whitney U test for
continuous variables. Univariate linear regression was used to
identify predictors of total and bioavailable vitamin D. Multivariate
linear regression models were employed to examine associations
of total and bioavailable vitamin D with symptom severity using a
PANSS 5-factor model that was previously published by our group
(Jiang et al., 2013). Positive factor items include delusion, halluci-
nation, suspiciousness, and unusual thought. Negative factor
items include emotional withdrawal, poor rapport, passive social
withdrawal, lack of spontaneity in conversation, and motor re-
tardation. Excitement factor items include hyperactivity, hostility,
and poor impulse control. Depression factor items include anxiety,
guilt-feeling and depression. Cognitive factor items include dis-
orientation and lack of judgment. In the regression models, we
adjusted for gender and ethnicity as these variables were found to
inﬂuence levels of vitamin D in the local population (Hawkins,
2013; 2009).3. Results
3.1. Comparison of FEP and control groups demographics
Overall, 31 patients with FEP and 31 controls were enrolled.
There was no signiﬁcant difference in age, gender, ethnicity and
smoking status distribution noted between the FEP group and the
control group. The FEP group was noted to have signiﬁcantly lower
Body Mass Index (BMI, t¼2.492, df¼60, p¼0.015) when com-
pared to controls (22.07 vs. 25.24) (Table 1).
3.2. Comparison of serum vitamin D levels
Although there was no signiﬁcant difference in baseline serum
albumin, calcium and total vitamin D levels between FEP and
control groups, the FEP group had higher levels of DBP (t¼2.479,
df¼55, p¼0.016) and lower levels of bioavailable vitamin D
(Mann-Whitney U¼280, p¼0.046) when compared to the control
group (Table 1).
Upon further analysis, there was a statistically signiﬁcant dif-
ference in total vitamin D levels between ethnic groups (F¼7.913,
df¼2, 54, p¼0.001). A Bonferroni post-hoc revealed that the ser-
um total vitamin D level was statistically signiﬁcantly lower in
Malays (45.83722.83 nmol/L, p¼0.001) when compared to Chi-
nese (70.20721.83 nmol/L) and no statistical signiﬁcance was
noted between Chinese and Indian (50.00710.00 nmol/L,
p¼0.280). A Krustal-Wallis H test showed that there was a sta-
tistically difference in serum bioavailable vitamin D between the
ethnic groups (X2¼6.351, df¼2, p¼0.042), with a mean rank
serum bioavailable vitamin D levels of 33.06 for Chinese, 23.11 for
Malays and 15.67 for Indians.
Table 1
Characteristics of study samples at baseline.
FEP (n¼31) Controls
(n¼31)
P-value
Age (years), mean (SD) 29.06 (9.73) 28.84 (9.76) 0.928
Gender, n(%) 1.000
Male 15 (48%) 14 (45%)
Female 16 (52%) 17 (55%)
Ethnicity, n(%) 1.000
Chinese 19 (61%) 19 (61%)
Malay 10 (32%) 10 (32%)
Indian 2 (7%) 2 (7%)
Smoking status, n(%) 0.569
Non-smoker 22 (71%) 24 (77%)
Smoker 9 (29%) 7 (23%)
BMI (kg/m2), mean (SD) 22.07 (5.01) 25.04 (5.00) 0.015
Duration of Untreated Pyschosis
(years), mean (SD)
1.80 (4.01) –
Serum albumin (mmol/L), mean
(SD)
565.07
(195.81)
609.72 (120.39) 0.284
Serum calcium (mmol/L), mean
(SD)
2.36 (0.05) 2.38 (0.05) 0.149
Serum DBP (mmol/L), mean (SD) 3.25 (1.56) 2.38 (1.07) 0.016
Total vitamin D (nmol/L), mean
(SD)
61.67 (26.69) 61.25 (22.56) 0.949
Bioavailable vitamin D (nmol/L),
mean (SD)
10.19 (5.67) 12.82 (6.60) 0.046
PANSS factor scores
Positive 8.90 (4.16) –
Negative 9.71 (4.15) –
Excitement 3.77 (1.31) –
Depression 7.06 (3.60) –
Cognitive 5.94 (2.19) –
Abbreviations: BMI: Body Mass Index, DBP: Vitamin D binding protein, PANSS:
Positive and Negative Syndrome Scale.
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levels of serum total vitamin D (73.52724.81 nmol/L vs.
50.58718.40 nmol/L, t¼3.991, df¼55, po0.001). We also noted a
statistically signiﬁcant higher serum bioavailable vitamin D
(Mann-Whitney U¼250, p¼0.013) in males (mean rank of 34.74)
than females (mean rank of 23.83).
Being overweight (BMI425 kg/m2) had no signiﬁcant effect on
vitamin D and bioavailable D levels in both FEP and control groups.
The 8 patients (25.8%) with a BMI of above 25 kg/m2 had mean
total vitamin D levels of 53.13722.63 nmol/L while non-over-
weight patients had mean levels of 65.26728.00 nmol/L
(t¼1.083, df¼25, p¼0.289). The 8 overweight patients had
mean bioavailable vitamin D levels of 9.7876.68 nmol/L whileTable 2
Association between serum total vitamin D and PANSS severity symptoms.
Total vitamin D
Unadjusted
β P-value 95% CI R2
Positivea 0.308 0.117 0.014–0.119 0.09
Negativeb 0.147 0.464 0.09–0.044 0.02
Excitementc 0.022 0.912 0.021–0.023 0.00
Depressiond 0.237 0.233 0.024–0.094 0.05
Cognitivee 0.214 0.284 0.055–0.017 0.04
a Delusion, hallucination, suspiciousness, and unusual thought.
b Emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneit
c Hyperactivity, hostility, and poor impulse control.
d Anxiety, guilt-feeling and depression.
e Disorientation and lack of judgment.non-overweight patients had mean levels of 10.3675.38 nmol/L
(t¼0.242, df¼25, p¼0.811).
There was no difference in mean total and bioavailable
vitamin D levels between smokers (72.92728.52 nmol/L and
11.7576.25 nmol/L) and non-smokers (58.45725.96 nmol/L and
9.7475.57 nmol/L) (t¼1.179, df¼25, p¼0.249 and t¼0.760,
df¼25, p¼0.455).
3.3. Factors predicting vitamin D levels
The factors known to affect vitamin D levels were determined
using univariate linear regression with total and log-transformed
bioavailable vitamin D as dependent variables and age, BMI, gen-
der, ethnicity, duration of untreated psychosis and smoking status
as independent variables.
Gender (F¼15.928, df¼1,55, po0.001, R2¼0.255), ethnicity
(F¼7.913, df¼2,54, p¼0.001, R2¼0.227), and BMI (F¼5.420,
df¼1,55, p¼0.024, R2¼0.090) were signiﬁcant predictors of total
vitamin D levels. Smoking status (F¼2.682, df¼1,55, p¼0.107,
R2¼0.046), duration of untreated psychosis (F¼2.698, df¼1,25,
p¼0.113, R2¼0.097) and age (F¼0.864, df¼1,55, p¼0.357,
R2¼0.015) were not signiﬁcant predictors of serum total vitamin D
level.
As for bioavailable vitamin D, gender (F¼9.135, df¼1,55,
p¼0.004, R2¼0.142), ethnicity (F¼5.956, df¼2,54, p¼0.005,
R2¼0.181), duration of untreated psychosis (F¼4.816, df¼1,25,
p¼0.038, R2¼0.162) were signiﬁcant predictors. BMI (F¼1.951,
df¼1,55, p¼0.168, R2¼0.034), smoking status (F¼2.890, df¼1,55,
p¼0.095, R2¼0.050), and age (F¼1.040, df¼1,55, p¼0.312,
R2¼0.019) were not associated with serum bioavailable vitamin D
levels.
3.4. Total and bioavailable vitamin D levels and symptom severity
The associations between total and bioavailable vitamin D levels
and symptom severity were examined via multivariate linear regres-
sion (Tables 2 and 3). We observed a signiﬁcant negative association
between bioavailable vitamin level and PANSS negative symptom
score after controlling for gender, ethnicity and DUP (Table 2).4. Discussion
This study is the ﬁrst, to our knowledge, to report on the as-
sociation between levels of both total and bioavailable vitamin D
in FEP patients in a country which receives regular sunlight
throughout the year.Adjusted for gender, ethnicity and DUP
β P-value 95% CI R2
5 0.384 0.189 0.035–0.166 0.143
2 0.174 0.513 0.122–0.063 0.264
0 0.172 0.560 0.023–0.042 0.297
6 0.302 0.309 0.044–0.133 0.099
6 0.018 0.950 0.056–0.053 0.093
y in conversation, and motor retardation.
Table 3
Association between serum bioavailable vitamin D and PANSS severity symptoms.
Bioavailable vitamin D
Unadjusted Adjusted for gender, ethnicity and DUP
β P-value 95% CI R2 β P-value 95% CI R2
Positivea 0.141 0.482 0.177 to 0.365 0.020 0.055 0.833 0.320 to 0.393 0.070
Negativeb 0.359 0.066 0.493 to 0.016 0.129 0.449 0.045 0.587 to 0.008 0.382
Excitementc 0.115 0.567 0.061 to 0.110 0.013 0.258 0.317 0.056 to 0.163 0.117
Depressiond 0.191 0.341 0.123 to 0.342 0.036 0.198 0.449 0.193 to 0.421 0.079
Cognitivee 0.139 0.489 0.191 to 0.094 0.019 0.043 0.868 0.170 to 0.200 0.094
a Delusion, hallucination, suspiciousness, and unusual thought.
b Emotional withdrawal, poor rapport, passive social withdrawal, lack of spontaneity in conversation, and motor retardation.
c Hyperactivity, hostility, and poor impulse control.
d Anxiety, guilt-feeling and depression.
e Disorientation and lack of judgment.
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gender and ethnicity were signiﬁcant predictors for both total and
bioavailable vitamin D in current study (Hawkins, 2013; 2009).
Levels of total and bioavailable vitamin D were lower in the Malay
and Indian ethnic groups compared to the Chinese. This observa-
tion may be explained by the darker skin pigmentation in the
Malay and Indian ethnic groups, which led to lower levels of vi-
tamin D after UVB radiation exposure due to competitive binding
between absorbed melanin and 7-dehydrocholesterol for UVB
photons (Brenner and Hearing, 2008).
Male participants had higher serum levels of total and bioa-
vailable vitamin D compared to female participants. Differences in
dressing styles due to culture or religious reasons between the
genders may be a possible explanation for such observation as
Asian women tend to take extra measures to avoid sun exposure
(Kung and Lee, 2006). Unfortunately, we did not record details of
dressing, use of sun block and duration of sun exposure in this study.
Contrary to previous reports, our results show no difference in
serum concentrations of total vitamin D between FEP and control
groups (Belvederi Murri et al., 2013; Itzhaky et al., 2012; Jamilian
et al., 2013). On the other hand, signiﬁcant differences were noted
in bioavailable vitamin D and DBP at baseline between FEP pa-
tients and controls. These differences could be due to genetic
variations in the GC gene which codes for DBP. As there are dif-
ferent binding coefﬁcients for various DBP genetic variations, the
use of DBP phenotype-speciﬁc binding coefﬁcients would affect
bioavailable vitamin D concentrations (Powe et al., 2013). DBP not
only allows circulating vitamin D to bind, it also plays important
roles in the elimination of dead or injured white blood cells,
macrophages activation and neutrophil chemotaxis during in-
ﬂammation (Ying et al., 2015). Therefore, a higher level of serum
DBP in FEP subjects may also suggest be a sign of inﬂammation.
Serum albumin was studied to be a signiﬁcant predictor of vitamin
D deﬁciency in uremic patients, therefore a lower serum albumin
level noted in the FEP group may suggest possible poorer nutri-
tional management compared to healthy controls (Bentli et al.,
2013; Yonemura et al., 2000).
Previous studies looking into relationships between total vita-
min D levels and symptom severity had reported equivocal results.
Out of four studies looking into possible associations between vi-
tamin D levels and illness severity, only Yuksel et al. (2014) and
Graham et al. (2015) noted signiﬁcant associations between serum
total vitamin D and PANSS positive and negative scores after
controlling factors affecting vitamin D levels. The other two stu-
dies did not ﬁnd any relationship between vitamin D levels and
symptom severity despite patients having signiﬁcantly lower vi-
tamin D levels than healthy controls (Crews et al., 2013; Itzhaky
et al., 2012).The present study detected a signiﬁcant association between
bioavailable vitamin D and negative symptoms after controlling
for gender, ethnicity, and DUP. This may suggest that negative
symptoms such as social withdrawal and amotivation, leading to
lesser time spent outdoor, hence the reduced sun exposure.
The strengths of this study include a consistent sampling time
for all participants to minimize diurnal variation (Rejnmark et al.,
2002). We also focused on FEP rather than chronic patients who
are more susceptible to poor nutrition, reduced self-care or un-
known usage of medications. Our study has certain limitations.
First, we are unable to address potential casual relationships be-
tween vitamin D and development of psychosis due to the case-
control design. Second, we did not gather information on sun
exposure, sunblock application, nutritional background, dietary
information and DBP genotypic information which are factors af-
fecting vitamin D levels. Thirdly, the lack of difference in total vi-
tamin D between FEP and healthy control groups may be due to
the heterogeneity of the FEP group. Majority of FEP patients were
outpatients, reﬂecting a milder disease severity, therefore lifestyle
activities may be similar to the healthy controls. Finally, current
study was unable to detect signiﬁcant associations due to small
sample size. A sample size of 128 participants is required to detect
a large effect (d¼0.5) with 80% power at p¼0.05.
In summary, this is the ﬁrst reported study to demonstrate a
reduction in bioavailable vitamin D in FEP patients and its asso-
ciation with negative symptoms. This study is unique as it ex-
amined vitamin D levels in a population where sun exposure is
mostly consistent throughout the year. Future studies of vitamin D
should consider looking into the effects of bioavailable vitamin D
and factors that might inﬂuence its activity and metabolism, as
well as exploring the relationship between bioavailable vitamin D
and cognitive function.Source of funding
This study was funded by the Singapore Ministry of Health's
National Medical Research Council under its Transition Award
(Grant no.: NMRC/TA/002/2012). The authors have no potential
conﬂict of interest to report.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.psychres.2016.07.003.
J.Y. Yee et al. / Psychiatry Research 243 (2016) 390–394394References
Abdullah, A.K., Khan, S., Mustafa, S.F., Qutubuddin, A.A., Davis, C.M., 2012. Vitamin D
status and cardiometabolic risk factors in long-term psychiatric inpatients.
Prim. Care Companion CNS Disord. 14 (1).
Belvederi Murri, M., Respino, M., Masotti, M., Innamorati, M., Mondelli, V., Pariante,
C., Amore, M., 2013. Vitamin D and psychosis: mini meta-analysis. Schizophr.
Res. 150 (1), 235–239.
Bentli, R., Taskapan, H., Toktaş, H., Ulutas, O., Ozkahraman, A., Comert, M., 2013.
Signiﬁcant Independent predictors of vitamin D deﬁciency in inpatients and
outpatients of a nephrology unit. Int. J. Endocrinol., 2013.
Brenner, M., Hearing, V.J., 2008. The protective role of melanin against UV damage
in human skin. Photochem. Photobiol. 84 (3), 539–549.
Crews, M., Lally, J., Gardner-Sood, P., Howes, O., Bonaccorso, S., Smith, S., Murray, R.
M., Di Forti, M., Gaughran, F., 2013. Vitamin D deﬁciency in ﬁrst episode psy-
chosis: a case-control study. Schizophr. Res. 150 (2–3), 533–537.
Dealberto, M.J., 2007. Why are immigrants at increased risk for psychosis? Vitamin
D insufﬁciency, epigenetic mechanisms, or both?. Med. Hypotheses 68 (2),
259–267.
Eyles, D.W., Burne, T.H., McGrath, J.J., 2013. Vitamin D, effects on brain develop-
ment, adult brain function and the links between low levels of vitamin D and
neuropsychiatric disease. Front. Neuroendocrinol. 34 (1), 47–64.
Eyles, D.W., Smith, S., Kinobe, R., Hewison, M., McGrath, J.J., 2005. Distribution of
the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem.
Neuroanat. 29 (1), 21–30.
Graham, K.A., Keefe, R.S., Lieberman, J.A., Calikoglu, A.S., Lansing, K.M., Perkins, D.O.,
2015. Relationship of low vitamin D status with positive, negative and cognitive
symptom domains in people with ﬁrst-episode schizophrenia. Early Interv.
Psychiatry 9 (5), 397–405.
Hawkins, R., 2013. Total 25-OH vitamin D concentrations in Chinese, Malays and
Indians. Ann. Lab. Med. 33 (2), 156–158.
Hawkins, R.C., 2009. 25-OH vitamin D3 concentrations in Chinese, Malays, and
Indians. Clin. Chem. 55 (9), 1749–1751.
Hedelin, M., Lof, M., Olsson, M., Lewander, T., Nilsson, B., Hultman, C.M., Wei-
derpass, E., 2010. Dietary intake of ﬁsh, omega-3, omega-6 polyunsaturated
fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a
cohort of 33,000 women from the general population. BMC Psychiatry 10, 38.
Higuchi, T., Komoda, T., Sugishita, M., Yamazaki, J., Miura, M., Sakagishi, Y., Ya-
mauchi, T., 1987. Certain neuroleptics reduce bone mineralization in schizo-
phrenic patients. Neuropsychobiology 18 (4), 185–188.
Itzhaky, D., Amital, D., Gorden, K., Bogomolni, A., Arnson, Y., Amital, H., 2012. Low
serum vitamin D concentrations in patients with schizophrenia. Isr. Med. Assoc.
J.: IMAJ 14 (2), 88–92.
Jamilian, H., Bagherzadeh, K., Nazeri, Z., Hassanijirdehi, M., 2013. Vitamin D, para-
thyroid hormone, serum calcium and phosphorus in patients with schizo-
phrenia and major depression. Int. J. Psychiatry Clin. Pract. 17 (1), 30–34.
Jiang, J., Sim, K., Lee, J., 2013. Validated ﬁve-factor model of positive and negative
syndrome scale for schizophrenia in Chinese population. Schizophr. Res. 143
(1), 38–43.
Johnsen, M.S., Grimnes, G., Figenschau, Y., Torjesen, P.A., Almas, B., Jorde, R., 2014.
Serum free and bio-available 25-hydroxyvitamin D correlate better with bone
density than serum total 25-hydroxyvitamin D. Scand. J. Clin. Lab. Invest. 74 (3),
177–183.
Khor, G.L., Chee, W.S., Shariff, Z.M., Poh, B.K., Arumugam, M., Rahman, J.A., Theo-
bald, H.E., 2011. High prevalence of vitamin D insufﬁciency and its association
with BMI-for-age among primary school children in Kuala Lumpur, Malaysia.
BMC public Health 11 (1), 95.
Kung, A.W., Lee, K.K., 2006. Knowledge of vitamin D and perceptions and attitudes
toward sunlight among Chinese middle-aged and elderly women: a population
survey in Hong Kong. BMC Public Health 6, 226.
McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Jarvelin, M.R., Chant, D.,
Isohanni, M., 2004. Vitamin D supplementation during the ﬁrst year of life and
risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 67 (2–3),
237–245.
McGrath, J.J., Burne, T.H., Feron, F., Mackay-Sim, A., Eyles, D.W., 2010.Developmental vitamin D deﬁciency and risk of schizophrenia: a 10-year up-
date. Schizophr. Bull. 36 (6), 1073–1078.
Menkes, D.B., Lancaster, K., Grant, M., Marsh, R.W., Dean, P., du Toit, S.A., 2012.
Vitamin D status of psychiatric inpatients in New Zealand's Waikato region.
BMC Psychiatry 12 (1), 68.
Moy, F.-M., Bulgiba, A., 2011. High prevalence of vitamin D insufﬁciency and its
association with obesity and metabolic syndrome among Malay adults in Kuala
Lumpur, Malaysia. BMC Public Health 11 (1), 735.
Nerhus, M., Berg, A.O., Dahl, S.R., Holvik, K., Gardsjord, E.S., Weibell, M.A., Bjella, T.
D., Andreassen, O.A., Melle, I., 2015. Vitamin D status in psychotic disorder
Patients and healthy Controls–the inﬂuence of ethnic background. Psychiatry
Res. 230 (2), 616–621.
Norelli, L.J., Coates, A.D., Kovasznay, B.M., 2010. A comparison of 25-hydroxyvitamin
D serum levels in acute and long-stay psychiatric inpatients: a preliminary
investigation. e-SPEN, Eur. e-J. Clini. Nutr. Metab. 5 (4), e187–e189.
Nurbazlin, M., Chee, W.S.S., Rokiah, P., Tan, A.T.B., Chew, Y.Y., Siti Nusaibah, A.R.,
Chan, S.P., 2013. Effects of sun exposure on 25 (OH) vitamin D concentration in
urban and rural women in Malaysia. Asia Pac. J. Clin. Nutr. 22 (3), 391.
Phabphal, K., Geater, A., Leelawattana, R., Sathirapunya, P., Sattawatcharawanich, S.,
Limapichat, K., 2009. Prevalence and risk factors of low bone mineral density
and 25-hydroxyvitamin D status in young healthy epileptic adult patients in a
tropical Asian country taking antiepileptic drug. Bone 45 (2), 232–237.
Powe, C.E., Evans, M.K., Wenger, J., Zonderman, A.B., Berg, A.H., Nalls, M., Tamez, H.,
Zhang, D., Bhan, I., Karumanchi, S.A., Powe, N.R., Thadhani, R., 2013. Vitamin
D-binding protein and vitamin D status of black Americans and white Amer-
icans. New Engl. J. Med. 369 (21), 1991–2000.
Ramason, R., Selvaganapathi, N., Ismail, N.H.B., Wong, W.C., Rajamoney, G.N., Chong,
M.S., 2014. Prevalence of vitamin D deﬁciency in patients with hip fracture seen
in an orthogeriatric service in sunny Singapore. Geriatr. Orthop. Surg. Rehabil. 5
(2), 82–86.
Rejnmark, L., Lauridsen, A.L., Vestergaard, P., Heickendorff, L., Andreasen, F., Mo-
sekilde, L., 2002. Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vi-
tamin D-binding protein in postmenopausal women: relationship to plasma
parathyroid hormone and calcium and phosphate metabolism. Eur. J. En-
docrinol./Eur. Fed. Endocr. Soc. 146 (5), 635–642.
Torrey, E.F., Torrey, B.B., Peterson, M.R., 1977. Seasonality of schizophrenic births in
the United States. Arch. Gen. Psychiatry 34 (9), 1065–1070.
Umhau, J.C., George, D.T., Heaney, R.P., Lewis, M.D., Ursano, R.J., Heilig, M., Hibbeln,
J.R., Schwandt, M.L., 2013. Low vitamin D status and suicide: a case-control
study of active duty military service members. PloS One 8 (1), e51543.
Valipour, G., Saneei, P., Esmaillzadeh, A., 2014. Serum vitamin D levels in relation to
schizophrenia: a systematic review and meta-analysis of observational studies.
J. Clin. Endocrinol. Metab. 99 (10), 3863–3872.
Vermeulen, A., Verdonck, L., Kaufman, J.M., 1999. A critical evaluation of simple
methods for the estimation of free testosterone in serum. J. Clin. Endocrinol.
Metab. 84 (10), 3666–3672.
Wakayo, T., Belachew, T., Vatanparast, H., Whiting, S.J., 2015. Vitamin D deﬁciency
and its predictors in a country with thirteen months of sunshine: the case of
school children in central ethiopia. PloS One 10, 3.
Wiboonchutikul, S., Sungkanuparph, S., Kiertiburanakul, S., Chailurkit, L.-o, Char-
oenyingwattana, A., Wangsomboonsiri, W., Chantratita, W., Ongphiphadhana-
kul, B., 2012. Vitamin D insufﬁciency and deﬁciency among HIV-1-infected
patients in a tropical setting. J. Int. Assoc. Physicians AIDS Care (JIAPAC),
1545109711432142.
Ying, H.-Q., Sun, H.-L., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Chen, J., Liu, X.,
Wang, S.-K., 2015. Circulating vitamin D binding protein, total, free and bioa-
vailable 25-hydroxyvitamin D and risk of colorectal cancer. Scientiﬁc reports 5.
Yonemura, K., Fujimoto, T., Fujigaki, Y., Hishida, A., 2000. Vitamin D deﬁciency is
implicated in reduced serum albumin concentrations in patients with end-
stage renal disease. Am. J. Kidney Dis.: Off. J. Natl. Kidney Found. 36 (2),
337–344.
Yüksel, R.N., Altunsoy, N., Tikir, B., Külük, M.C., Unal, K., Goka, S., Aydemir, C., Goka,
E., 2014. Correlation between total vitamin D levels and psychotic psycho-
pathology in patients with schizophrenia: therapeutic implications for add-on
vitamin D augmentation. Ther. Adv. Psychopharmacol. 4 (6), 268–275.
